Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder

Potkin, S.G.; Kujawa, Mary J.; Carson, William H.; Saha, A.R.; Ali, Mazen Khalil; Ингенито, Г.

doi:10.1016/s0920-9964(03)80511-x

Cited by 18 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Potkin et al (69) presented data from a short-term (4-weeks) trial involving 404 patients that indicate that neither at 20 nor at 30 mg/day does aripiprazole increase prolactin levels. In fact, mean serum prolactin levels decreased from baseline levels in both groups (20 mg/day: -6.6 ng/mL and 30 mg/day: -6.4 ng/mL).…”

Section: Dopamine (Da) Receptor Activitymentioning

confidence: 99%

“…Five short-term (4 weeks) clinical trials were conducted to evaluate the effectiveness of aripiprazole in inpatients with an acute relapse of schizophrenia or schizoaffective disorder (19,23,43,67,69,70). A brief summary of short-term clinical trials is presented in Table 2.…”

Section: Schizophrenia and Related Disordersmentioning

confidence: 99%

“…Improvement in efficacy measures occurred within one week; these improvements were maintained through the end of the 4-week studies. In one risperidone-controlled study (69), 404 patients from 40 medical centers in the United States underwent a 5-day placebo washout period before their assignment to either aripiprazole (20 or 30 mg/day), risperidone (6 mg/day), or placebo. Results indicated that at either dose aripiprazole was superior to placebo and comparable to risperidone in efficacy.…”

Section: Schizophrenia and Related Disordersmentioning

confidence: 99%

“…Also, 42% of the patients treated with aripiprazole completed the trial compared with 21% in the placebo group. The second study (69,70) involved 347 patients with acute mania in a 12-week flexibly dosed trial of aripiprazole (15 to 30 mg/day) vs. haloperidol (10 to 15 mg/day). Again, response was primarily defined as a 50% or greater reduction in the YMRS total scores.…”

Section: Mood Disordersmentioning

confidence: 99%

See 3 more Smart Citations

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

2004

View full text Add to dashboard Cite

Aripiprazole (Abilify ® ) is an atypical antipsychotic drug that has been recently introduced for clinical use in the treatment of schizophrenia. Aripiprazole has a unique pharmacologic profile that includes partial agonism at several G-protein coupled receptors (GPCRs) [especially dopamine (D 2 ) and 5-HT 1A ] and antagonistic action at others (especially 5-HT 2A ). Clinical trials indicate that aripiprazole is effective in treating the positive and negative symptoms of schizophrenia. In short-term studies rapid onset of action (within one week) has been demonstrated. Preliminary data indicate that aripiprazole may also be effective in the treatment of manic symptoms of bipolar disorder. At recommended doses, aripiprazole appears to be safe and well tolerated in most adult patients with schizophrenia and schizoaffective disorder. There is only limited information available on the use of aripiprazole in children and adolescents, and pilot data suggest that a revised dosing strategy, based on weight, is indicated in this population. In the long-term studies, the use of aripiprazole was associated with continued efficacy, good compliance and increased time-to-relapse.Aripiprazole represents the first functionally selective atypical antipsychotic drug.

show abstract

Section: Dopamine (Da) Receptor Activitymentioning

confidence: 99%

Section: Schizophrenia and Related Disordersmentioning

confidence: 99%

Section: Schizophrenia and Related Disordersmentioning

confidence: 99%

Section: Mood Disordersmentioning

confidence: 99%

See 2 more Smart Citations

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

2004

View full text Add to dashboard Cite

show abstract

“…Several randomized, double-blind, placebo-controlled trials have shown that aripiprazole is an effective, safe, and well-tolerated treatment for schizophrenia (including acute schizophrenia) and schizoaffective disorders (Kane et al, 2002;Marder et al, 2003;Potkin et al, 2003). However, only a few studies with an open-label design (Takahashi et al, 2009;Lee et al, 2010) have been conducted on patients with first-episode psychosis or schizophrenia, which provides a window of opportunity for identification of the best practices.…”

Section: Introductionmentioning

confidence: 99%

The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis

Park

Cho²,

Hahn

et al. 2014

International Clinical Psychopharmacology

View full text Add to dashboard Cite

We investigated the efficacy and safety of aripiprazole in first-episode psychosis and explored the association between early response and later response to this medication. This was a 6-week, open-label, multicenter trial. The study population consisted of 59 patients with a DSM-IV diagnosis of a schizophreniform disorder, schizoaffective disorder, schizophrenia, or psychotic disorder not otherwise specified. The primary outcome measures were the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity scale. To assess the safety, we measured the drug-related adverse events, weight, and lipid-related variables. The sensitivity, specificity, positive predictive value, and negative predictive value were calculated for the response status at weeks 2 and 3 to predict the subsequent response at week 6. Among the 59 participants, 38 were able to complete the 6-week trial. Treatment with aripiprazole resulted in significant improvement in the PANSS and Clinical Global Impression scores over time. The response rate (defined as a ≥30% decrease in the PANSS total score from baseline to the last observation) was 69.1%. The most accurate prediction of later response in terms of negative predictive value and specificity was a reduction in the PANSS total score from baseline to week 3 of at least 20%. Aripiprazole had a modest side effect burden and was characterized by a safe profile with respect to weight and metabolic side effects. These results indicate that aripiprazole is effective and safe in the treatment of first-episode psychosis. The response at week 3, rather than week 2, predicted the later response more accurately.

show abstract

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

Davis

Chen²,

Glick³

2003

Arch Gen Psychiatry

886

492

View full text Add to dashboard Cite

show abstract

Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder

Cited by 18 publications

References 0 publications

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

Contact Info

Product

Resources

About